Gilead Sciences Seeks Product Diversification as Major Drug Exclusivities Approach Expiration, Eyes FDA Approval for Innovative HIV Prevention Treatment

As Gilead Sciences navigates a pivotal moment with major drug exclusivities nearing expiration, the spotlight is on its innovative HIV prevention treatment, lenacapavir, awaiting FDA approval. Can Gilead successfully diversify its portfolio while maintaining its leadership in HIV care amidst these challenges?